Live Analyst Rating Changes 9190 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Anthony Petrone
MIZU
Anthony Petrone
Wall Street Analyst
★★☆☆☆
#2329
on 13Foresight · ranked by our own returns
42%
Success Rate
+4.8%
Average Return
22 of 53 calls profitable · -126.2% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 42% of Anthony Petrone's ratings turned a profit when each position was held for 1 year — averaging +4.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

104 Buy 28 Hold 0 Sell
Anthony's Stock Coverage 40 ratings · 2026-07-16
Company Date Position Consensus Price Target 1-Yr Return
BSX
Boston Scientific
Jul 15, 2026 BUY Strong Buy
+73.2% avg upside
38 analysts
$70.00
62.61% Upside
·
CH:ALC
Alcon
Jul 15, 2026 BUY Buy
+29.1% avg upside
35 analysts
$64.47
16.15% Upside
·
ESTA
Establishment Labs Holdings
Jul 15, 2026 BUY Strong Buy
-3.3% avg upside
12 analysts
$105.00
15.94% Upside
+0.2%
SENS
Senseonics Holdings
Jul 15, 2026 BUY Strong Buy
+189.9% avg upside
13 analysts
$18.00
249.54% Upside
·
LIVN
LivaNova
Jul 15, 2026 BUY Strong Buy
-0.3% avg upside
15 analysts
$95.00
19.71% Upside
·
ADMA
ADMA Biologics
Jul 15, 2026 BUY Strong Buy
+46.5% avg upside
15 analysts
$17.00
95.93% Upside
+0.0%
LNTH
Lantheus
Jul 15, 2026 BUY Strong Buy
-25.7% avg upside
20 analysts
$120.00
15.09% Upside
-0.1%
TNDM
Tandem Diabetes Care
Jul 15, 2026 HOLD Strong Buy
+112.1% avg upside
29 analysts
$20.00
30.84% Upside
+0.0%
TFX
Teleflex
Jul 15, 2026 HOLD Buy
+35.1% avg upside
20 analysts
$145.00
10.06% Upside
·
RMD
Resmed
Jul 15, 2026 BUY Buy
+17.7% avg upside
27 analysts
$220.00
10.76% Upside
·
ISRG
Intuitive Surgical
Jul 15, 2026 HOLD Strong Buy
+34.7% avg upside
36 analysts
$500.00
28.62% Upside
+3.0%
HAE
Haemonetics
Jul 15, 2026 BUY Buy
-10.9% avg upside
17 analysts
$90.00
17.30% Upside
·
EW
Edwards Lifesciences
Jul 15, 2026 BUY Strong Buy
+12.0% avg upside
34 analysts
$105.00
20.30% Upside
+1.0%
DXCM
Dexcom
Jul 15, 2026 BUY Strong Buy
+36.6% avg upside
32 analysts
$90.00
23.73% Upside
+0.0%
MDT
Medtronic
Jun 03, 2026 BUY Buy
+19.9% avg upside
38 analysts
$100.00
24.27% Upside
+2.6%
MMED
MiniMed Group, Inc.
Jun 03, 2026 BUY Strong Buy
+41.2% avg upside
13 analysts
$21.00
36.17% Upside
+9.3%
COO
Cooper Co
Jun 03, 2026 BUY Buy
+90.4% avg upside
21 analysts
$85.00
20.41% Upside
+14.1%
STAA
Staar Surgical
May 14, 2026 HOLD Hold
+19.3% avg upside
16 analysts
$27.00
5.30% Downside
-9.8%
MNKD
MannKind
May 07, 2026 BUY Buy
+74.1% avg upside
22 analysts
$7.00
71.08% Upside
+15.2%
EMBC
Embecta Corporation
May 06, 2026 HOLD Sell
+140.1% avg upside
5 analysts
$5.00
55.31% Upside
-10.2%
INSP
Inspire Medical Systems
May 05, 2026 BUY Buy
+64.0% avg upside
21 analysts
$55.00
8.95% Upside
-2.7%
GEHC
GE Healthcare Technologies Inc
Apr 30, 2026 BUY Buy
+30.4% avg upside
22 analysts
$80.00
26.58% Upside
+6.4%
GKOS
Glaukos
Apr 30, 2026 BUY Strong Buy
-9.6% avg upside
21 analysts
$160.00
1.94% Upside
+6.1%
MDXG
MiMedx Group
Apr 30, 2026 BUY Strong Buy
+148.5% avg upside
17 analysts
$8.00
87.39% Upside
+25.0%
AXGN
AxoGen
Apr 29, 2026 BUY Strong Buy
-13.0% avg upside
21 analysts
$55.00
41.95% Upside
-4.8%
ABT
Abbott Laboratories
Apr 20, 2026 HOLD Strong Buy
+30.6% avg upside
36 analysts
$115.00
28.78% Upside
-6.3%
TEM
Tempus AI, Inc. Class A
Apr 13, 2026 BUY Strong Buy
+17.0% avg upside
20 analysts
$100.00
74.75% Upside
+18.3%
PLSE
Pulse Biosciences
Apr 13, 2026 BUY Strong Buy
+18.5% avg upside
5 analysts
$30.00
13.91% Upside
+34.6%
GH
Guardant Health
Jun 13, 2025 BUY Strong Buy
-9.5% avg upside
31 analysts
$65.00
60.08% Downside
+167.0%
ZBH
Zimmer Biomet Holdings
Nov 05, 2021 BUY Buy
+22.8% avg upside
38 analysts
$175.00
94.08% Upside
-23.1%
LMAT
Lemaitre Vascular
Sep 16, 2021 BUY Strong Buy
+2.1% avg upside
15 analysts
$70.00
29.77% Downside
-14.1%
TELA
TELA Bio
Aug 11, 2021 BUY Strong Buy
+1037.6% avg upside
8 analysts
$20.00
2446.72% Upside
-37.6%
TARS
Tarsus Pharmaceuticals
Aug 10, 2021 BUY Strong Buy
+34.8% avg upside
16 analysts
$45.00
21.77% Downside
-29.1%
IART
Integra Lifesciences
May 20, 2021 BUY Buy
+124.7% avg upside
21 analysts
$86.00
357.89% Upside
-15.6%
CTSO
Cytosorbents
Sep 17, 2020 BUY Strong Buy
+2938.2% avg upside
13 analysts
$15.00
3757.09% Upside
+0.0%
VREX
Varex Imaging
Aug 13, 2020 HOLD Strong Buy
+88.0% avg upside
9 analysts
$18.00
66.86% Upside
+115.0%
VRAYQ
Viewray
Dec 03, 2019 BUY Strong Buy
+558333233.4% avg upside
12 analysts
$7.00
699999900.06% Upside
-17.8%
ARAY
Accuray
Aug 17, 2018 BUY Buy
+2229.0% avg upside
9 analysts
$6.00
2082.60% Upside
-27.1%
OSIS
OSI Systems
Aug 25, 2017 BUY Strong Buy
+2.1% avg upside
11 analysts
$93.00
57.32% Downside
-8.6%
PRGO
Perrigo Company
Aug 02, 2016 HOLD Hold
+573.4% avg upside
20 analysts
$97.00
855.71% Upside
-20.7%
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Anthony Petrone — Frequently Asked Questions
How accurate are Anthony Petrone's stock ratings?
Based on the calls 13Foresight could measure, about 37% of Anthony's ratings were profitable over a one-year hold, with an average return of +4.9% per rating, or -145.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Anthony ranked on 13Foresight?
Anthony Petrone is currently ranked #2329 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Anthony cover?
Anthony most recently has ratings on BSX, CH:ALC, ESTA, SENS, LIVN, ADMA, LNTH, TNDM, TFX, RMD, ISRG, HAE and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.